COLOGNE, GERMANY / ACCESSWIRE / June 28, 2018 / CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors today announced the ...

COLOGNE, GERMANY / ACCESSWIRE / February 9, 2017 / CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced ...

ELEVECTA(R) takes viral vector manufacturing to the next level to serve the rapidly growing market of gene therapy applications Growing serum-free in suspension, ELEVECTA(R) producer cell lines enable ...

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities. Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of ...

CEVEC Pharmaceuticals has announced its new management team: Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed ...

Cytiva, backed by a $1.5 billion investment from its parent company, the Danaher Group, continued its expansion tear with the acquisition of CEVEC Pharmaceuticals. CEVEC, which is based in Cologne, ...

The new cell-line producing platform enables fully scalable production of high-performance adeno-associated virus vectors. On April 28, 2020, Cevec Pharmaceuticals announced the launch of the ELEVECTA ...

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, ...

CEVEC Pharmaceuticals has announced the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will ...

Companies claim CAP platform demonstrates stable and high protein expression along with flexibility to generate new custom lines. Contract R&D company Aragen Bioscience signed a strategic license ...

Cologne, Germany, December 21, 2010 / b3c newswire / - CEVEC Pharmaceuticals, the developer of the CAP® protein expression system derived from human amniocytes, today announced that Rainer Christine ...